Research
Peptide half-life and the dosing schedule
Half-life is the clock inside a dosing schedule. Across approved peptide drugs it runs from under two minutes to about a week, and that spread is mostly engineering rather than biology.
What half-life measures
Half-life is the time it takes for the amount of a drug in your blood to fall by half. It is a rate, not a duration.
The number matters because it sets how often a drug has to be given to keep its level steady. A molecule that halves every ten minutes is gone within an hour. A molecule that halves every week is still measurable a month later.
Approved drug labels publish this figure in the clinical pharmacology section. It is one of the few numbers about a peptide that is measured, reviewed and printed rather than asserted.
Unmodified peptides disappear in minutes
A peptide is a short chain of amino acids, and your body is extremely good at taking those apart. Enzymes cut the chain, and the kidneys filter out the pieces.
The approved liraglutide label puts a number on how fast this happens to a natural hormone. Native GLP-1 has a half-life of 1.5 to 2 minutes, because two enzymes degrade it: dipeptidyl peptidase 4, usually shortened to DPP-4, and neutral endopeptidase.
That is the baseline any injected peptide starts from. Left unmodified, a peptide hormone is a signal designed to be switched off quickly, and the body switches it off quickly.
Three engineering tricks buy time
Every long-acting peptide drug on the market got that way by design. The labels describe the design.
The first trick is enzyme resistance. Liraglutide is stable against both DPP-4 and neutral endopeptidase, and semaglutide is stabilized against DPP-4 as well. Changing one or two amino acids removes the site the enzyme cuts.
The second is albumin binding. Semaglutide and tirzepatide each carry a fatty acid chain that latches onto albumin, the most abundant protein in blood. The semaglutide label calls albumin binding the principal mechanism behind its long half-life, because a bound drug is not filtered by the kidney and is shielded from degradation. Both are bound to plasma albumin at above 99 percent.
The third is slow absorption. The liraglutide label credits self-association at the injection site, which means the molecules clump loosely and release over hours instead of all at once.
The ladder, from minutes to a week
Reading the approved labels side by side shows how wide the range is, and how closely the schedule follows it.
Tesamorelin has an elimination half-life of 8 minutes in one approved vial formulation and 11 minutes in the other, and both are labeled for injection once daily. Exenatide has a terminal half-life of 2.4 hours and is labeled twice daily, before two main meals. Bremelanotide has a mean terminal half-life of about 2.7 hours, with a range of 1.9 to 4.0 hours, and is labeled for use as needed.
Liraglutide has an elimination half-life of about 13 hours, and its label says that profile is what makes once-daily administration suitable. Tirzepatide has a half-life of about 5 days, which the label says enables once-weekly dosing. Semaglutide has an elimination half-life of about one week.
The pattern is not subtle. The schedule printed on a label is downstream of the number printed in section 12.
A short half-life does not mean a short effect
This is where the intuition breaks, and it breaks in a way sellers sometimes exploit.
Tesamorelin clears in about ten minutes, yet it is given once a day and its label carries warnings about sustained changes in the body. It works by prompting the pituitary to release growth hormone, which in turn raises insulin-like growth factor 1. The label states that tesamorelin stimulates growth hormone production and increases serum IGF-1, that the effects of prolonged IGF-1 elevation are unknown, and that IGF-1 should be monitored during treatment.
So the drug is gone long before the effect is. Half-life describes how long the molecule lasts, not how long its consequences last, and the two can differ by orders of magnitude.
The reverse also holds. A long half-life does not guarantee a lasting benefit, because a drug can circulate for weeks while doing very little.
Two products, one molecule, different documents
Tesamorelin is sold in the United States as two approved products with two separate labels. One reports a half-life of 8 minutes, the other 11 minutes, and the two use different vial formulations and different reconstitution instructions.
The labels state directly that the two products are not substitutable. Same molecule, same manufacturer, different documents, and a rule against swapping them.
That is the clearest available illustration of a general point. A peptide is not a product. The formulation, the concentration, the diluent and the instructions are what turn a molecule into something a person can be given, and they differ even when the name on the front does not.
A long half-life is also a commitment
The semaglutide label makes the trade explicit. With an elimination half-life of about one week, semaglutide is present in the circulation for about five weeks after the last dose.
A once-weekly injection is convenient. It also means stopping is slow, and a side effect cannot be reversed by skipping the next one. The overdose section of the label tells clinicians to plan for a prolonged period of observation.
Neither direction is better. They are different trade-offs, and the label is where both are written down.
What to check on a peptide product page
Start with whether a half-life figure exists at all. For the peptides sold without an approved product behind them, there is no label to read, so any schedule offered rests on something other than reviewed pharmacokinetic data.
Then check whether a claimed schedule matches the molecule. Weekly dosing for a peptide drug is a result of specific chemistry, usually a fatty acid chain and enzyme-resistant substitutions. An unmodified short chain does not acquire a weekly schedule by being sold in a larger vial.
Then check whether the citation behind a figure studied the same form and the same route. A half-life measured after intravenous infusion does not describe a subcutaneous injection, and a figure from one salt form does not automatically describe another.
Your own instructions come from your prescriber and the leaflet in your carton. Nothing here is a schedule to follow.
Key takeaways
- Half-life is how fast a drug level halves, and it sets how often a drug must be given.
- Native GLP-1 has a half-life of 1.5 to 2 minutes, which is the baseline an unmodified peptide starts from.
- Long-acting peptide drugs get that way through enzyme resistance, albumin binding and slow absorption.
- Approved labels run from 8 minutes for tesamorelin to about one week for semaglutide, and the schedules follow.
- A short half-life can still produce sustained effects, because the drug and its consequences are different clocks.
- Two approved tesamorelin products report different half-lives and their labels say they are not substitutable.
Frequently asked questions
Why do some peptides need daily injections and others weekly?
Because their half-lives differ by orders of magnitude, and approved labels tie the schedule to that figure. Tesamorelin clears with a half-life of 8 to 11 minutes and is labeled once daily. Liraglutide is about 13 hours and its label calls that suitable for once-daily use. Tirzepatide is about 5 days, which the label says enables once-weekly dosing, and semaglutide is about one week. The long ones were engineered to be long.
What makes a peptide last longer in the body?
Three things, all described in approved labels. Resistance to the enzymes that cut peptide chains, chiefly DPP-4 and neutral endopeptidase. Binding to albumin, usually through an attached fatty acid, which shields the drug from kidney filtration and degradation; semaglutide and tirzepatide are each bound at above 99 percent. And slow release from the injection site, which the liraglutide label attributes to self-association.
Does a short half-life mean the effect wears off quickly?
No, and tesamorelin is the counterexample. It clears in about ten minutes but acts by prompting a growth hormone release that raises IGF-1, and its label warns that the effects of prolonged IGF-1 elevation are unknown and directs monitoring. Half-life describes the molecule. The chain of events it starts can outlast it by a wide margin.
Can I compare the half-life of two different peptides?
You can compare the numbers, but the comparison rarely settles anything on its own. A longer half-life is not a measure of potency, quality or benefit; it is a measure of how slowly a molecule is cleared. It tells you how often a drug has to be given and how long it lingers after you stop, which are logistics and safety questions rather than efficacy questions.
Where do I find the half-life of a peptide I have been offered?
In the clinical pharmacology section of an FDA-approved label, usually numbered 12.3, published on DailyMed and on the FDA label database. If the peptide has no approved product anywhere, that section does not exist for it, and a half-life quoted on a product page is coming from somewhere else. Check what it was measured in, by what route, and in which form of the substance.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- OZEMPIC (semaglutide) injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, June 2026
- MOUNJARO (tirzepatide) injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, August 2026
- VICTOZA (liraglutide) injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, October 2025
- EGRIFTA WR (tesamorelin) for injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, July 2026
- EGRIFTA SV (tesamorelin) for injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, July 2026
- VYLEESI (bremelanotide) injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, November 2025
- BYETTA (exenatide) injection — FDA-approved prescribing information — National Library of Medicine, DailyMed, September 2025